drugset / Trial / NCT02011971

Cognitive Effects of Vinpocetine in Healthy Adults and Patients With Epilepsy

NCT02011971 ↗

Phase 1/2 Suspended 30 enrolled Stanford University
RandomizedCrossoverQuadruple-blindTreatment

Summary

Pilot studies in healthy volunteers and in patients with epilepsy to assess the potential efficacy and safety of different dosages of vinpocetine in improving cognition.

Timeline

Start
2012-02
Primary completion
2026-12
Completion
2026-12

Outcome

Outcome not reported

Stopped: “We are now considering revision of the IND to determine maximum tolerated dose”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Vinpocetine Small molecule 10 mg Oral
Comparator Vinpocetine Small molecule 20 mg Oral
Comparator Vinpocetine Small molecule 60 mg Oral

Indications